Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.65 |
| ▸ | LCK | P06239 | 7/20 | 0.65 |
| ▸ | TEK | Q02763 | 7/20 | 0.65 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.50 |
| ▸ | BRAF | P15056 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4715351 | 0.88 | LCK (0.78) | KDRLCKTEKBRAFCA12 | |
| SCHEMBL4719939 | 0.88 | KDR (0.54) | KDRLCKTEKPDGFRB | |
| SCHEMBL4715363 | 0.87 | LCK (0.67) | KDRLCKTEKBRAFFLT3 | |
| SCHEMBL4719717 | 0.85 | KDR (0.61) | KDRLCKTEKPDGFRBCA12 | |
| SCHEMBL4618708 | 0.85 | LCK (0.85) | KDRLCKTEKPDGFRBKIT | |
| SCHEMBL4714365 | 0.84 | LCK (0.65) | KDRLCKTEKRIPK1PDGFRB | |
| SCHEMBL16008176 | 0.83 | CA12 (0.54) | KDRRIPK1PDGFRBBRAFCA12 | |
| SCHEMBL4716338 | 0.83 | KDR (0.57) | KDRLCKTEKPDGFRB | |
| SCHEMBL4716714 | 0.82 | LCK (0.58) | KDRLCKTEKKITFLT3 | |
| SCHEMBL4041879 | 0.82 | LCK (0.71) | KDRLCKTEKBRAFKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737463-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | claimed |
| EP-1737463-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | TIE1, TEK, TEKT1 | KDR 5/4885LCK 391/4885TEK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.